Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 1
Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
Panelists discuss how current treatment approaches for transplant-ineligible newly diagnosed multiple myeloma patients are evolving with the addition of anti-CD38 therapies to standard VRd backbone, while examining unmet needs and the role of MRD negativity as an endpoint through recent trial data including CEPHEUS.